---
{"dg-publish":true,"permalink":"/Reference notes/Readwise/Tweets/Emergencies in Hematolo...-2/"}
---

# 😱Emergencies in Hematolo...

![rw-book-cover](https://pbs.twimg.com/profile_images/1566858765609193486/5rq5awvk.jpg)

## Metadata
- Author: [[@NicoGagelmann on Twitter\|@NicoGagelmann on Twitter]]
- Full Title: 😱Emergencies in Hematolo...
- Category: #tweets
- URL: https://twitter.com/NicoGagelmann/status/1656654670784516097

## Highlights
- 😱Emergencies in hematology😱 
  Tumor lysis syndrome (TLS) 
  A short 🧵 #MedTwitter
  1/19 
  ![](https://pbs.twimg.com/media/Fv2dzg5aUAYW22G.png) ([View Tweet](https://twitter.com/NicoGagelmann/status/1656654670784516097))
- What's TLS?
  -major comorbidity in the management of hematologic malignancies and one of the major conditions young colleagues should
  👉know to detect and to handle❗️
  -modern definition of TLS is based on the Cairo–Bishop criteria for laboratory and clinical TLS 
  2/19 
  ![](https://pbs.twimg.com/media/Fv2S3oiX0AE-zi4.png) ([View Tweet](https://twitter.com/NicoGagelmann/status/1656654674819424257))
- Clinical TLS:
  -simply defined as laboratory TLS with the addition of an elevated creatinine not attributable to
  - - another cause
  - - 🫀arrhythmia/sudden death
  - - seizures
  -given newer treatment/preventive measures, both forms of TLS may have clinical implications
  3/19 https://t.co/H9NZr17rYg ([View Tweet](https://twitter.com/NicoGagelmann/status/1656654679277969412))
- History:
  -phenomenon of chemotherapy-induced TLS became apparent soon after effective therapies for leukemia and lymphoma were discovered early in 20th century
  -several reports published describing uric acid nephropathy and acute failure within days after treatment
  4/19 
  ![](https://pbs.twimg.com/media/Fv2TYf6WcAI-32j.jpg) ([View Tweet](https://twitter.com/NicoGagelmann/status/1656654683199655936))
- Pathogenesis I:
  -lysis of tumour cells👉release of cell contents, incl electrolytes, proteins and nucleic acids
  - nucleic acid and protein contents are quickly broken down in the liver👉production of uric acid 
  ![](https://pbs.twimg.com/media/Fv2UG9bXoAQmxzT.png) ([View Tweet](https://twitter.com/NicoGagelmann/status/1656654686756417536))
- Pathogenesis II:
  -release of potassium & phosphorus
  -rapid increases in potassium, sometimes potentiated by renal failure👉arrhythmias -hypocalcaemia (Ca2+ phosphorus precipitation & tissue deposition)👉muscle cramps, tetany, arrhythmias, seizures
  6/19 
  ![](https://pbs.twimg.com/media/Fv2UKl0XgAEV3CW.png) ([View Tweet](https://twitter.com/NicoGagelmann/status/1656654690216726528))
- Pathogenesis III:
  -mechanism behind acute injury is multi-factorial -hyperuricemia👉direct crystallization within renal tubules
  -uric acid-induced renal vasoconstriction tissue hypoxia, reperfusion injury & local inflammation
  7/19 
  ![](https://pbs.twimg.com/media/Fv2UWHFWYAcMPdG.png) ([View Tweet](https://twitter.com/NicoGagelmann/status/1656654693807038465))
- Risk stratification:
  -serum creatinine, arrhythmia and/or seizures, with the most severe clinical sequela determining the grade
  BUT
  -expert opinion, not validated prospectively
  -acute failure >50% but only ~1% show seizures
  8/19 
  ![](https://pbs.twimg.com/media/Fv2UkFvWwAYhRvM.png) ([View Tweet](https://twitter.com/NicoGagelmann/status/1656654697451905025))
- In general:
  -severity of TLS may depend on the cancer mass, potential for lysis of tumor cells, characteristics of the patient and supportive care
  -the greater the cancer mass, the greater the quantity of cellular contents released after anticancer therapy
  9/19 https://t.co/BW4h314zG9 ([View Tweet](https://twitter.com/NicoGagelmann/status/1656654702078201857))
- Patient history matters!
  -perhaps a more clinically relevant is identification of patients at highest risk
  -CML considered low-risk, as is CLL
  BUT
  iCLL classified as intermediate-risk if WBC >50×10^9/l or if treated with targeted therapies such as venetoclax
  10/19 
  ![](https://pbs.twimg.com/media/Fv2Vh6iWYAIGSKX.jpg) ([View Tweet](https://twitter.com/NicoGagelmann/status/1656654708872974336))
- Drug-associated TLS (selection):
  -all anti-CD20 monoclonal antibody therapies
  -ibrutinib, lenalidomide, pazopanib, trastuzumab
  -venetoclax (ramp-up!)
  -paclitaxel, radiation, corticosteroids, fludarabine, immune checkpoint inhibitors...
  11/19 
  ![](https://pbs.twimg.com/media/Fv2WibHX0AAgSFH.png) ([View Tweet](https://twitter.com/NicoGagelmann/status/1656654712408776705))
- Prevention:
  -CRITICAL
  -hydration is backbone for prevention/treatment
  - - goal: improve volume status and create the optimal environment forexcretion of uric acid and phosphate
  - - rules of 👍 i~3 l/m2/day or targeting urine output of at least 100–150 ml/h
  12/19 
  ![](https://pbs.twimg.com/media/Fv2XYhiWYAEg6Xu.png) ([View Tweet](https://twitter.com/NicoGagelmann/status/1656654716590505985))
- Controversy "urine alkalization":
  -may prevent uric acid crystal formation
  BUT
  -can ⬇️xanthine solubility👉promote crystal formation
  -can ⬆️Ca2+ phosphate precipitates
  -allopurinol can lead to xanthinuria
  -alkalization+allopurinol not currently recommended
  13/19 https://t.co/UTfXf2tHRL ([View Tweet](https://twitter.com/NicoGagelmann/status/1656654721464299520))
- Allopurinol:
  -xanthine oxidase inhibitor
  - -⬇️serum uric acid levels
  - - ⬇️risk of uric acid crystallization and acute renal failure
  -recommended: daily for adults 600–800 mg (into 2–3 doses)
  -lower dose eg 300 mg often utilized
  -started 1–2 days prior to chemo + hydration
  14/19 
  ![](https://pbs.twimg.com/media/Fv2ZoENXgAUrl5o.png) ([View Tweet](https://twitter.com/NicoGagelmann/status/1656654725260120064))
- Rasburicase:
  -recombinant urate oxidase
  -converting uric acid to allantoin
  -rapid and high efficacy (median 1 day)
  BUT
  -no randomized trial showed superiority vs allopurinol
  -recommended for high risk
  -general practice: if the baseline uric acid is >8 mg/dl
  15/19 
  ![](https://pbs.twimg.com/media/Fv2aQJKaQAIUlS-.jpg) ([View Tweet](https://twitter.com/NicoGagelmann/status/1656654728850444289))
- CAVE:
  -patients with glucose-6-phosphate dehydrogenase deficiency (G6PD) are at risk for acute haemolytic anaemia after administration of rasburicase
  -FDA recommends performing G6PD enzyme activity testing in patients at higher risk for G6PD deficiency
  16/19 
  ![](https://pbs.twimg.com/media/Fv2bYz6aQAMocuX.png) ([View Tweet](https://twitter.com/NicoGagelmann/status/1656654731820015628))
- Febuxostat:
  -another oral xanthine oxidase inhibitor
  -pharmacologic advantage over allopurinol: inhibits both oxidized+reduced form of xanthine oxidase👉potency⬆️ and no need for dose adjustment in renal failure
  BUT
  -FLORENCE trial showed NO difference to allopurinol 
  17/19 
  ![](https://pbs.twimg.com/media/Fv2bFo-aUAU49yX.png) ([View Tweet](https://twitter.com/NicoGagelmann/status/1656654735045431297))
- Prognosis:
  -often not the principle cause of mortality (infections, sepsis!)
  -eg in AML, only ~5% show clinical TLS
  BUT
  👉 associated with a much higher death rate (~70% vs 25% for laboratory)
  -adapt for risk and patient characteristics❗️
  18/19 https://t.co/UmHoCVlnU4 ([View Tweet](https://twitter.com/NicoGagelmann/status/1656654748458848258))
- TLS summary:
  ❗️Emergency
  ❗️Monitor: lab+clinical (🫘 failure, 🫀arrhythmias, seizures)
  ❗️Risk stratify: disease, morbidity, treatment
  ❗️Secure venous access
  ❗️Prevention/treatment: HYDRATION, allopurinol for lower and +rasburicase for higher risk
  #MedTwitter https://t.co/G5j6j6ZeWj ([View Tweet](https://twitter.com/NicoGagelmann/status/1656654752112074755))
- References & resources:
  https://t.co/HDvz3pTngD
  https://t.co/nBnTcTTQVp
  https://t.co/oDUJqIWf2H
  https://t.co/rgtKgkiyuL https://t.co/R1G9Lb8ZPj ([View Tweet](https://twitter.com/NicoGagelmann/status/1656654755249418242))
